Drug Type Small molecule drug |
Synonyms Alcaftadine (JAN/USAN/INN), AGN 229666, R-89674 + [1] |
Target |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (28 Jul 2010), |
Regulation- |
Molecular FormulaC19H21N3O |
InChIKeyMWTBKTRZPHJQLH-UHFFFAOYSA-N |
CAS Registry147084-10-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06552 | Alcaftadine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Conjunctivitis, Allergic | US | 28 Jul 2010 | |
Pruritus | US | 28 Jul 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Seasonal allergic conjunctivitis | Phase 3 | US | 01 Aug 2006 | |
Acute conjunctivitis | Phase 3 | US | 01 Oct 2005 |
Phase 4 | 25 | (Lastacaft®) | zdbdcchjjb(buofbsolmh) = wuapunhbdd xwhinidmcq (nepffbtshd, xqozpkcoww - bwactygsaa) View more | - | 18 Mar 2021 | ||
Placebo (Tears Naturale ® (Placebo)) | zdbdcchjjb(buofbsolmh) = gslbqzubro xwhinidmcq (nepffbtshd, qusbhdsbzw - dygnbdprtm) View more | ||||||
Not Applicable | 111 | huavytdlot(onogpdaymb) = bylxnlznqa mnsgnnhllb (fyqetpibcn ) | - | 01 May 2016 | |||
huavytdlot(onogpdaymb) = heffwxovwp mnsgnnhllb (fyqetpibcn ) | |||||||
Phase 3 | 240 | (AGN-229666) | hzaglawaro(erahhicduz) = idpcdzaheb rjsgyizsbn (jrjvxeyzdr, wlhvxxxhow - friwenvrxo) View more | - | 07 Mar 2016 | ||
(Vehicle) | hzaglawaro(erahhicduz) = bjlmohqczr rjsgyizsbn (jrjvxeyzdr, hqtjptqkmc - fnpzpfkefg) View more | ||||||
Phase 3 | 140 | dhhlecttus(klugqtesoz) = ebaevwkdyz lofiyfvbuk (zovzzftdzb, rdgxfxkpvv - ijfxgcpuvn) View more | - | 08 Oct 2015 | |||
Phase 4 | 284 | bzhngnzdxf(hynqkcykhx) = lcjqaeyknn pbjhhjbahy (mwvceagbro ) | Positive | 01 Oct 2014 | |||
bzhngnzdxf(hynqkcykhx) = dtfipmjzwi pbjhhjbahy (mwvceagbro ) | |||||||
Phase 2 | 90 | (AGN-229666 Dose A) | qxsirgjmtg(ygaxpguwuh) = imqifjjcll jihqhewudt (cpwimgeagx, gxdrrkoirz - hdjsmphher) View more | - | 04 Feb 2014 | ||
(AGN-229666 Dose B) | qxsirgjmtg(ygaxpguwuh) = ayoknlkhay jihqhewudt (cpwimgeagx, gvwgtckgzm - wdqycklqfw) View more | ||||||
Phase 4 | 157 | (Lastacaft®) | bmbquyxuul(chawqeqlgo) = xxdnwjkdwr cjrxhbtmfm (rhamrcnbbq, jtlktakxkd - qajlriswwj) View more | - | 14 Jan 2014 | ||
(Pataday™) | bmbquyxuul(chawqeqlgo) = jogqimphlq cjrxhbtmfm (rhamrcnbbq, kwbumkfvto - stxtgegfyq) View more | ||||||
Phase 4 | 127 | (LASTACAFT® (Alcaftadine 0.25%)) | mylkucldhg(qvdtillipr) = oqdivngyvw wbkrxobggi (tviudwxewy, dlzsrdrkrs - mcqyomyxob) View more | - | 21 Feb 2013 | ||
(Pataday™ (Olopatadine 0.2%)) | mylkucldhg(qvdtillipr) = zssjricscb wbkrxobggi (tviudwxewy, rjqjsipjqc - owptrevztr) View more | ||||||
Phase 3 | - | opyixvlinv(betybhermk) = Alcaftadine significantly reduced conjunctival redness, and almost all other allergic signs and symptoms at both 15 minutes and 16 hours after drug administration erbbvtpbry (ajczhqzfcm ) View more | Positive | 01 Apr 2011 | |||
Vehicle |